A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

Start Date31 Jan 2024

Sponsor / Collaborator

Cumberland Pharmaceuticals, Inc.

NCT03340675

/ CompletedPhase 2

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new therapeutic strategy for patients with DMD.
Funding Source - FDA OOPD

Start Date19 Oct 2020

Sponsor / Collaborator

Cumberland Pharmaceuticals, Inc.

[+1]

NCT03962855

/ CompletedPhase 2IIT

The Thromboxane Receptor Antagonist to Block the Effects of Non-Platelet Thromboxane Generation and Improve Endothelial Function (TRAP) Trial

This study evaluates whether addition of the thromboxane receptor antagonist to chronic aspirin therapy improves endothelial function and reduces non-platelet thromboxane generation in patients with established cardiovascular disease. Half of participants will receive ifetroban and the other half will receive matching placebo for the 4 week study period.

Start Date20 Sep 2019

Sponsor / Collaborator

American Heart Association, Inc.

[+1]

100 Clinical Results associated with Ifetroban

100 Translational Medicine associated with Ifetroban

100 Patents (Medical) associated with Ifetroban

Literatures (Medical) associated with Ifetroban

01 Mar 2025·PHARMACEUTICAL CHEMISTRY JOURNAL

Prediction of the Drug’s Clearance Correlation Between Humans and Rats

Author: Shayanfar, Ali ; Navaei, Kiana Shabani

Animal species, i.e. rats, are used to evaluate a drugs biol. activity and pharmacokinetics, such as clearance.This study aims to develop a predictive method to evaluate the relationship between the clearance of drugs in rats and humans.Adataset of 395 drugs composed of human and rat clearance data was applied in this study.The drugs, according to the clearance differences, were divided into two groups on the basis of the correlation between humans and rats.Structural parameters were used to develop a model to estimate the class of each drug by binary logistic regression.The results showed that the developed models are a useful way to show which drug have an acceptable correlation between human and rat clearance by using structural features.They can be used to determine the group of drugs with an accuracy of 74%.According to the validation results, the developed method has an acceptable accuracy for checking the relationship between the clearance of drugs in humans and rats.This modeling can be used to exclude the drugs from experiments in rats which reveal a considerable difference between the clearance of humans and that of rats.

01 Oct 2024·EUROPEAN RESPIRATORY JOURNAL

Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension

Review

Author: Galiè, Nazzareno ; Zamanian, Roham ; Psotka, Mitchell A. ; Cascino, Thomas M. ; Wilkins, Martin R. ; Weatherald, Jason ; Cascino, Thomas M ; Wilkins, Martin R ; Seeger, Werner ; Gomberg-Maitland, Mardi ; Fleming, Thomas R ; Fleming, Thomas R. ; Psotka, Mitchell A

Clinical trials in pulmonary arterial hypertension (PAH) have led to the approval of several effective treatments that improve symptoms, exercise capacity and clinical outcomes. In phase 3 clinical trials, primary end-points must reflect how a patient “feels, functions or survives”. In a rare disease like PAH, with an ever-growing number of treatment options and numerous candidate therapies being studied, future clinical trials are now faced with challenges related to sample size requirements, efficiency and demonstration of incremental benefit on traditional end-points in patients receiving background therapy with multiple drugs. Novel clinical trial end-points, innovative trial designs and statistical approaches and new technologies may be potential solutions to tackle the challenges facing future PAH trials, but these must be acceptable to patients and regulatory bodies while preserving methodological rigour. In this World Symposium on Pulmonary Hypertension task force article, we address emerging trial end-points and designs, biomarkers and surrogate end-point validation, the concept of disease modification, challenges and opportunities to address diversity and representativeness, and the use of new technologies such as artificial intelligence in PAH clinical trials.

01 Sep 2023·The Journal of allergy and clinical immunology

Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease

Article

Author: Jing Cui ; Chongjia C. Chen ; Joshua A. Boyce ; Katherine N. Cahill ; Laura Cho ; Jonathan Hacker ; Chunli Feng ; Kathleen M. Buchheit ; Meghan Le ; Elliot Israel ; Tanya M. Laidlaw

BACKGROUND:

Aspirin-exacerbated respiratory disease (AERD) is the triad of asthma, nasal polyposis, and respiratory reactions to COX-1 inhibitors. Overproduction of cysteinyl leukotrienes and underproduction of prostaglandin E₂ (PGE₂) are hallmarks of AERD. A mouse model predicted a key role for the thromboxane-prostanoid (TP) receptor in AERD.

OBJECTIVE:

Our aim was to determine whether ifetroban, a TP receptor antagonist, attenuates aspirin-induced respiratory symptoms in patients with AERD.

METHODS:

A total of 35 patients with AERD completed a 4-week double-blinded, placebo-controlled trial of ifetroban and underwent an oral aspirin challenge. The primary outcome was change in the provocative dose of aspirin that caused a 2-point increase in Total Nasal Symptom Score. Changes in lung function, eicosanoid levels, and platelet and mast cell activation were assessed. Cultured human nasal fibroblasts were stimulated with or without the TP agonist U46619 and assayed for prostanoid production.

RESULTS:

Ifetroban was well tolerated in AERD and did not change the mean 2-point increase in Total Nasal Symptom Score (P = .763). Participants taking ifetroban had greater aspirin-induced nasal symptoms and a greater decline in FEV₁ value than did participants receiving placebo (-18.8% ± 3.6% with ifetroban vs -8.4% ± 2.1% with placebo [P = .017]). Four weeks of ifetroban significantly increased urinary leukotriene E₄ levels and decreased nasal PGE₂ levels compared with placebo. Peak aspirin-induced urinary thromboxane levels correlated with peak urinary leukotriene E₄ and prostaglandin D₂ metabolite levels in participants taking ifetroban. U46119 significantly potentiated the production of PGE₂ by cultured nasal fibroblasts from subjects with AERD but not by cultured nasal fibroblasts from controls without polypoid sinusitis.

CONCLUSION:

Contrary to our hypothesis, TP receptor blockade worsened aspirin-induced reactions in AERD, possibly by exacerbating dysregulation of the eicosanoid system. TP signaling on stromal cells may be critical to maintaining PGE₂ production when COX-2 function is low.

News (Medical) associated with Ifetroban

13 Jul 2026

·www.prnewswire.com

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Record Date is July 10, 2026 & Payment Date is July 31,2026 Corporate and Insider Share Purchase Initiatives to Continue NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock. The dividend will be payable on July 31, 2026, to the shareholders of record at the close of business on July 10, 2026. Cumberland previously announced the closing of a Strategic Transaction with Apotex Health, resulting in the integration of the U.S.-branded businesses. Cumberland received $100 million in cash at closing for its line of FDA-approved products. In addition, Cumberland expects to receive up to $11 million in additional payments associated with product inventory and transitional support services. Following the closing of the Apotex transaction, an analysis by the company's tax advisors, along with refined financial projections, indicated greater net cash from the transaction than originally projected. Therefore, Cumberland's Board of Directors met to assess the Company's future cash needs and evaluate possible options for returning capital to shareholders. In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5 million in Cumberland shares over time. Several Board members will also be establishing new share purchase plans to increase their holdings in the Company. "In keeping with our ongoing commitment to deliver value to our shareholders, we are issuing a special dividend following the strategic transaction, which treats all shareholders equally," said A,J. Kazimi, Cumberland's CEO. "After the payout of $1.50 per share, we believe the Company will still have significant liquidity and financial flexibility to fund our long-term product development efforts, with additional reserves available to address any new opportunities". Cumberland has retained its robust portfolio of innovative product candidates and its majority ownership position in Cumberland Emerging Technologies Inc. Following the closing, Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases: Duchenne Muscular Dystrophy Cardiomyopathy: Cumberland announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with this rare, fatal genetic neuromuscular disease. Interactions with the FDA have been underway regarding study results and requirements for approval. The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations. Systemic Sclerosis: Cumberland has conducted a Phase II clinical study evaluating the safety of ifetroban in patients with this debilitating autoimmune disorder. Evaluation of the study data is underway with top-line results anticipated as the next milestone. Idiopathic Pulmonary Fibrosis: A Phase II study evaluating ifetroban in patients with the most common form of progressive fibrosing interstitial lung disease is actively enrolling at medical centers across the U.S. Favorable interim safety findings have been announced, and the next milestone is the announcement of the efficacy results. Cancer Metastasis: Cumberland, in collaboration with Vanderbilt Health, recently announced the results of a Pilot Study of ifetroban in patients with high-risk solid tumors. The findings suggest the potential to block cancer metastasis, as a favorable trend was identified with fewer deaths due to metastatic disease in those receiving ifetroban rather than a placebo. The Phase 2 clinical trial also found ifetroban to be safe and well tolerated in the oncology patients, supporting further development of the drug to prevent cancer metastasis. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis. For more information, please visit . SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

Phase 2Fast TrackOrphan DrugClinical Result

13 Jul 2026

·investor.cumberlandpharma.com

/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./

/C O R R E C T I O N – Cumberland Pharmaceuticals Inc. / In the news release, CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE, issued July 13, 2026 by Cumberland Pharmaceuticals Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Record Date is July 23, 2026 & Payment Date is July 31,2026 Corporate and Insider Share Purchase Initiatives to Continue NASHVILLE, Tenn. , July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock. The dividend will be payable on July 31, 2026 , to the shareholders of record at the close of business on July 23, 2026 . Cumberland previously announced the closing of a Strategic Transaction with Apotex Health, resulting in the integration of the U.S .-branded businesses. Cumberland received $100 million in cash at closing for its line of FDA-approved products. In addition, Cumberland expects to receive up to $11 million in additional payments associated with product inventory and transitional support services. Following the closing of the transaction with Apotex , an analysis by the company's tax advisors, along with refined financial projections, indicated greater net cash from the transaction than originally projected. Therefore, Cumberland's Board of Directors met to assess the Company's future cash needs and evaluate possible alternatives for the excess capital. In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5 million in Cumberland shares over time. The timing and actual number of shares repurchased pursuant the Company's repurchase program will be determined by management depending on a variety of factors, including stock price, trading volume, market conditions, and other general business considerations. Several Board members will also be establishing new share purchase plans to increase their holdings in the Company. "In keeping with our ongoing commitment to deliver value to our shareholders, we are issuing a special dividend following the strategic transaction, which treats all shareholders equally," said A,J. Kazimi, Cumberland's CEO. "After the payout of $1.50 per share, we believe the Company will still have significant liquidity and financial flexibility to fund our long-term product development efforts, with additional reserves available to address any new opportunities". Cumberland has retained its robust portfolio of innovative product candidates and its majority ownership position in Cumberland Emerging Technologies Inc . Following the closing, Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases: Duchenne Muscular Dystrophy Cardiomyopathy: Cumberland announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with this rare, fatal genetic neuromuscular disease. Interactions with the FDA have been underway regarding study results and requirements for approval. The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations. Systemic Sclerosis: Cumberland has conducted a Phase II clinical study evaluating the safety of ifetroban in patients with this debilitating autoimmune disorder. Evaluation of the study data is underway with top-line results anticipated as the next milestone. Idiopathic Pulmonary Fibrosis: A Phase II study evaluating ifetroban in patients with the most common form of progressive fibrosing interstitial lung disease is actively enrolling at medical centers across the U.S . Favorable interim safety findings have been announced, and the next milestone is the announcement of the efficacy results. Cancer Metastasis: Cumberland, in collaboration with Vanderbilt Health , recently announced the results of a Pilot Study of ifetroban in patients with high-risk solid tumors. The findings suggest the potential to block cancer metastasis, as a favorable trend was identified with fewer deaths due to metastatic disease in those receiving ifetroban rather than a placebo. The Phase 2 clinical trial also found ifetroban to be safe and well tolerated in the oncology patients, supporting further development of the drug to prevent cancer metastasis. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis. For more information, please visit www.cumberlandpharma.com. Correction: The current version of the release has "July 10" in the sub-headline and first paragraph updated to "July 23", updated verbiage in the beginning and end of the third paragraph, and a sentence added after the first sentence of the fourth paragraph. View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-special-dividend-of-1-50-per-share-302823903.html SOURCE Cumberland Pharmaceuticals Inc. Emily Kent, Dalton Agency, (540) 621-5448

Phase 2Orphan DrugFast TrackClinical Result

01 Jul 2026

·www.prnewswire.com

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on Rare Disease Pipeline NASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp. ("Apotex"), the largest Canadian-based pharmaceutical company, to integrate their branded U.S. businesses. Under the terms of the agreement, Apotex has acquired Cumberland's line of branded pharmaceuticals for cash consideration of $100 million funded at closing, which followed approval by Cumberland's shareholders. "We are pleased to complete this value-creating transaction, which was strongly supported by our shareholders with over 99% of the votes cast in favor of the transaction," said A.J. Kazimi, CEO of Cumberland. "This milestone significantly strengthens our financial position, enabling us to focus on the large market opportunities associated with our pipeline programs. Our goals are to deliver innovative new products to improve patient care, while continuing to build value for our shareholders." Cumberland has retained its robust portfolio of innovative product candidates and its majority ownership position in Cumberland Emerging Technologies Inc. Following the closing, Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases: Duchenne Muscular Dystrophy Cardiomyopathy: Cumberland announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with this rare, fatal genetic neuromuscular disease. Interactions with the FDA have been underway regarding study results and requirements for approval. The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations. Systemic Sclerosis: Cumberland has conducted a Phase II clinical study evaluating the safety of ifetroban in patients with this debilitating autoimmune disorder. Evaluation of the study data is underway with top-line results anticipated as the next milestone. Idiopathic Pulmonary Fibrosis: A Phase II study evaluating ifetroban in patients with the most common form of progressive fibrosing interstitial lung disease is actively enrolling at medical centers across the U.S. Favorable interim safety findings have been announced and the next milestone is the announcement of the efficacy results. Cancer Metastasis: Cumberland, in collaboration with Vanderbilt Health, recently announced the results of a Pilot Study of ifetroban in patients with high-risk solid tumors. The findings suggests the potential to block cancer metastasis, as a favorable trend was identified with fewer deaths due to metastatic disease in those receiving ifetroban rather than a placebo. The Phase 2 clinical trial also found ifetroban to be safe and well tolerated in the oncology patients, supporting further development of the drug to prevent cancer metastasis. About Apotex Apotex (APTX.TO), is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more at About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is a Nashville-based biopharmaceutical company focused on developing new therapies for rare diseases. The company is advancing a late-stage pipeline of product candidates through a series of late stage clinical studies. The treatments are being developed across multiple therapeutic areas to address serious patient conditions that represent unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis. For more information, please visit . Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to meet FDA standards or supply Cumberland's products on a timely basis, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

Phase 2Orphan DrugClinical ResultFast Track

100 Deals associated with Ifetroban

External Link

KEGG	Wiki	ATC	Drug Bank
D04500	Ifetroban	-	DB12321

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic Pulmonary Fibrosis	Phase 2	United States	Cumberland Pharmaceuticals, Inc.	31 Jan 2024
Cardiomyopathy, Dilated	Phase 2	United States	Vanderbilt University Medical Center	19 Oct 2020
Cardiomyopathy, Dilated	Phase 2	United States	Cumberland Pharmaceuticals, Inc.	19 Oct 2020
Muscular Dystrophy, Duchenne	Phase 2	United States	Vanderbilt University Medical Center	19 Oct 2020
Muscular Dystrophy, Duchenne	Phase 2	United States	Cumberland Pharmaceuticals, Inc.	19 Oct 2020
Malignant Solid Neoplasm	Phase 2	United States	Cumberland Pharmaceuticals, Inc.	12 Dec 2018
Hypertension, Portal	Phase 2	United States	Cumberland Pharmaceuticals, Inc.	06 Mar 2017
Liver Cirrhosis	Phase 2	United States	Cumberland Pharmaceuticals, Inc.	06 Mar 2017
Limited Scleroderma	Phase 2	United States	Cumberland Pharmaceuticals, Inc.	01 Jan 2017
Limited Scleroderma	Phase 2	India	Cumberland Pharmaceuticals, Inc.	01 Jan 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03340675 (FIGHT DMD \| DMD, CTgov)	Phase 2	Cardiomyopathy, Dilated \| Muscular Dystrophy, Duchenne	46	Ifetroban (High Dose Ifetroban)	juifpudiwo(heggrpjrlo) = xlniympdld cuwrnwwiio (ogrehllkuh, 2485) View more	-	26 Jan 2026
				Ifetroban (Low Dose Ifetroban)	juifpudiwo(heggrpjrlo) = ylpocrghlu cuwrnwwiio (ogrehllkuh, 585) View more
NCT03340675 (MDA2025)	Phase 2	Muscular Dystrophy, Duchenne	41	High-dose ifetroban (300 mg)	cwzoocrgtp(tfesxriapl) = utynkdsnqa jdybplvzdk (pzlammqcsy, 5.4)	Positive	16 Mar 2025
				Placebo	-
NCT03340675 (FIGHT DMD, PRNewswire \| Company_Website) Manual	Phase 2	Muscular Dystrophy, Duchenne	41	IfetrobanIfetroban 150 mg/day	soezycaema(hchaczlukk) = xuqysvjtez nijnrchjwd (xnsbqtreds )	Positive	04 Feb 2025
				Ifetroban 300 mg/day	soezycaema(hchaczlukk) = bbkqrtjxjq nijnrchjwd (xnsbqtreds )
NCT03962855 (TRAP, CTgov)	Phase 2	Cardiovascular Diseases	57	Ifetroban Sodium (Ifetroban)	anoslibtrc(fvbgndqnyg) = ggddjsryvu vcktdshryi (ttrhwvdbyo, ohpudlvgpg - akndusdsys) View more	-	05 Dec 2024
				Placebo (Placebo)	anoslibtrc(fvbgndqnyg) = wjzswmvnuv vcktdshryi (ttrhwvdbyo, ehaubcapak - wwfrchehpf) View more
NCT03028350 (CTgov)	Phase 2	Asthma, Nasal Polyps, and Aspirin Intolerance	54	Ifetroban Oral Capsule (Ifetroban Oral Capsule)	iehbcauvud(wrsjrzbgoh) = auevqptjht ubxobqzetz (aiilfsdshz, 12.9) View more	-	28 Jun 2024
				Placebo Oral Capsule (Placebo Oral Capsule)	iehbcauvud(wrsjrzbgoh) = ufikvytblp ubxobqzetz (aiilfsdshz, 22.6) View more
NCT03326063 (CTgov)	Phase 2	Asthma, Nasal Polyps, and Aspirin Intolerance \| Asthma aspirin-sensitive	38	Ifetroban (Ifetroban)	gdwlhnnden(ajpcyvofpx) = hvessmgqxp kaapetzhvr (hniolemljo, 48) View more	-	14 Jul 2023
				Placebo (Placebo)	gdwlhnnden(ajpcyvofpx) = kekyirrjva kaapetzhvr (hniolemljo, 46) View more
FDA Funded Phase 2 Clinical Trial (MDA2023)	Phase 2	Muscular Dystrophy, Duchenne	-	Ifetroban	wiweatilyw(darlaaqhyc) = awncvxvceo noyzsnutkd (ymoerngfio )	Positive	19 Mar 2023
				Control (Placebo)	wiweatilyw(darlaaqhyc) = yvwnnwkrde noyzsnutkd (ymoerngfio )
NCT02802228 (CTgov)	Phase 2	Hypertension, Portal \| Liver Cirrhosis	30	Ifetroban (Ifetroban)	jmssraxvbj = obtclvhmlz xxnxabkewp (eahdgkuzel, akgehhmbxd - olkmzhyyal) View more	-	19 Jan 2022
				Placebo (Placebo)	jmssraxvbj = sgnjrvrtcc xxnxabkewp (eahdgkuzel, kiknbngnzd - nequukvezq) View more
NCT02216357 (CTgov)	Phase 2	Asthma, Nasal Polyps, and Aspirin Intolerance	19	Ifetroban, Oral Capsule (Ifetroban, Oral Capsule)	cmacldekeb = odaaohhrxf lbrvjmfuff (qzcjpqsvkb, azssikdxkv - nnuqjqranc) View more	-	22 Mar 2017
				Placebo, Oral Capsule (Placebo, Oral Capsule)	cmacldekeb = eqaavctetk lbrvjmfuff (qzcjpqsvkb, xvaqckbtmw - omrkgbwfrj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis